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Available online 16 January 2016Intermittent administration of human parathyroid hormone (1–34)[hPTH(1–34)] induces anabolic action on the
bones. To understand themechanism underlying the early phase of hPTH(1–34)-induced anabolic action, we in-
vestigated the expression proﬁles of osterix and sclerostin after short-term intermittent administration of hPTH
(1–34) using immunohistochemistry in adult rats. In the cancellous bone, hPTH(1–34) administration greatly in-
creased the number of osterix-positive cells in the bone marrow on day 1, but the cells gradually decreased on
days 3 and 5. Injections of hPTH(1–34) induced no signiﬁcant changes in the number of sclerostin-positive oste-
ocytes in the cancellous bone. In the cortical bone, intermittent administration of hPTH(1–34) signiﬁcantly re-
duced the number of sclerostin-positive osteocytes. The serum sclerostin level was downregulated and the
osteocalcin level was upregulated on day 5 after intermittent administration of hPTH(1–34). Intermittent
hPTH(1–34) injections increased osteoblast surface, osteoid thickness, and osteoid surface in cancellous bone,
but not in cortical bone. This study suggested that the increase in osterix-positive osteoprogenitors in cancellous
bone and the decrease in sclerostin-positive osteocytes in cortical bone play important roles in anabolic action on
osteogenesis induced by short-term administration of hPTH(1–34).
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Various hormones regulate bone metabolism. Among these, para-
thyroid hormone (PTH) has dual effects on bone formation and resorp-
tion (Silva and Bilezikian, 2015). In various animal experimentalmodels
and human cases (Reeve et al., 1976; Tam et al., 1982; Dempster et al.,
1993; Wronski et al., 1993; Dobnig and Turner, 1995; Recker et al.,
2009; Hanyu et al., 2012; Jilka, 2007), aswell as cell culture experiments
(Ishizuya et al., 1997; Nishida et al., 1994), intermittent administration
of human PTH(1–34) [hPTH(1–34)] (Reeve et al., 1976; Tam et al.,
1982; Dobnig and Turner, 1995; Hanyu et al., 2012; Jilka, 2007) or
human PTH(1–84) [hPTH[1–84] (Tam et al., 1982; Recker et al., 2009)
has been shown to have an anabolic effect, such as increasing the
bone mass by stimulating bone formation more than bone resorption.
In contrast, continuous treatment with PTH results in decreased boner, Tokyo Dental College, Tokyo
. This is an open access article undermass due to enhanced bone resorption than formation, as demonstrated
in various animal experimental models (Silva and Bilezikian, 2015).
However, the precise mechanism of how PTH affects bone metabolism,
especially its anabolic action at early phase, remains unclear.
We along with other researchers have shown that hPTH(1–34) in-
jections increased the number of colony forming unit-ﬁbroblastic
(CFU-F) and CFU-alkaline phosphatase-positive (CFU-ALP), which pre-
sumably are osteoprogenitors (Nishida et al., 1994; He et al., 2013).
These results suggest that hPTH(1–34) stimulates the proliferation
and differentiation of osteoprogenitor cells in the bone marrow. Osteo-
blast differentiation is regulated by speciﬁc transcriptional factors, in-
cluding Runx2 (Komori et al., 1997) and osterix (Nakashima et al.,
2002). Research has indicated that osterix works as a downstream tran-
scription factor of Runx2 during osteoblast differentiation (Komori et al.,
1997; Nakashima et al., 2002; Yamaguchi et al., 2000; Komori, 2011).
Mizoguchi et al. (2014) found that osterixmarks distinct waves of prim-
itive and deﬁnite stromal progenitors during bone marrow develop-
ment. In addition, they showed that osterix labeling is restricted in the
osteolineage cells of the adult mouse bone marrow (Mizoguchi et al.,
2014). These results led us to explore the distribution of osterix-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ministration at the early phase.
Sclerostin is encoded by the SOST gene, which is primarily produced
by osteocytes (Kousteni and Bilezikian, 2008; Kramer et al., 2010; Ke
et al., 2012; Weivoda and Oursler, 2014). Sclerostin binds to low-
density lipoprotein receptor-related proteins (LRP) 4, 5, and 6 to inhibit
Wnt signaling (Kousteni and Bilezikian, 2008; Kramer et al., 2010; Ke
et al., 2012; Weivoda and Oursler, 2014; Tu et al., 2015). Several lines of
evidence indicate that PTH is a suppressor of Sost expression (Bellido
et al., 2005; Keller and Kneissel, 2005; Silvestrini et al., 2007; Drake
et al., 2010; Leupin et al., 2007; Ardawi et al., 2012). In rodent models,
however, the effects of hPTH(1–34) on sclerostin expression vary. Bellido
et al. showed that in lumbar vertebrae ofmice, continuous administration
of hPTH(1–34) markedly downregulated Sost mRNA and the sclerostin
protein, but intermittent administration transiently suppressed Sost
mRNA after hPTH(1–34) administration, which then turned to control
levels (Bellido et al., 2005). Keller et al., however, reported that intermit-
tent administration of hPTH(1–34) induced sustained suppression of Sost
mRNA in the femoral cortical bone of estrogen-deprived rats (Keller and
Kneissel, 2005). These results prompted us to investigate whether inter-
mittent hPTH(1–34) administration exerts different effects on the sup-
pression of sclerostin in cancellous and cortical bone. In previousFig. 1. Effects of PTH administration on the distribution of osterix-positive cells in cancellous bo
group (upperpanels) anddaily hPTH(1–34) injection group (lower panels). The sectionswere im
Day 1, 3, and 5 indicate the days after administration of saline or hPTH(1–34). The black area
section incubated with nonimmunized rabbit IgG as a substitute for the primary antibody. Sca
bone marrow (B) and the number of osterix-positive osteoblasts on the cancellous bone surfa
bars: daily hPTH(1–34) injection group. Statistical analyses for two groupswere performed by S
hPTH(1–34) injection group versus daily hPTH(1–34) injection group on day 3]. ††p b 0.01. Stat
tiple comparisons test. *p b 0.05, **p b 0.01. n = 7–8 for each group.research, we found that cortical bone retained extremely greater number
of sclerostin-positive osteocytes than cancellous bone using immunoﬂuo-
rescent imaging in the femurs of 3-day-old and 2- and 4-week-old rats
(Watanabe et al., 2012). Since the effects of hPTH(1–34) on sclerostin ex-
pression in cancellous and cortical bone have not been well established,
these studies may contribute to a better understanding of the regulatory
mechanism of sclerostin by hPTH(1–34).
In this study, we demonstrated the effects of intermittent administra-
tion of hPTH(1–34) on the expression of osterix and sclerostin in the pe-
riod shortly following the treatment. Osterix expression is preferentially
upregulated by hPTH(1–34) in bone marrow cells in cancellous bone,
while sclerostin expression is preferentially downregulated in cortical
bone. These ﬁndings indicate that intermittent hPTH(1–34) administra-
tion exerts its anabolic action through differentmechanisms in cancellous
and cortical boneduring the early phase after hPTH(1–34) administration.
2. Materials and methods
2.1. Experimental animals
Twelve-week-old female Sprague–Dawley rats (Charles River,
Kanagawa, Japan) were used for this experiment. The rats werene. (A) Immunoﬂuorescence of osterix-positive cells in the cancellous bone of the control
munostained for osterix (green) and counterstainedwith nuclear propidium iodide (red).
represents concellous bone and the red area is bone marrow. Negative control shows the
le bars: 100 μm. Time course of the changes in the number of osterix-positive cells in the
ce (C). Open bars: control group, hatched bars: single hPTH(1–34) injection group, black
tudent's t-test [control group versus daily hPTH(1–34) injection group on day 1, and single
istical analyses for data sets withmore than two groupswere compared by Dunnett's mul-
Fig. 3. Effects of hPTH(1–34) administration on the distribution of sclerostin-positive osteocytes in cancellous bone. (A)Distribution of sclerostin-positive osteocytes in the cancellous bone
with or without hPTH(1–34) treatment on day 5. Sclerostin-positive cells are shown in green. The nucleus is red. The black area represents cancellous bone and the red area is bone
marrow. The area surrounded by the square at the right bottom of the hPTH(1–34) injected group shows high magniﬁcation of the area demarcated by the yellow square in the center
of the picture. Negative control shows the section incubated with nonimmunized goat IgG as a substitute for the primary antibody. Scale bars: 50 μm. (B) Time course of the changes
in the percentage of sclerostin-positive osteocytes in total osteocytes in cancellous bone. Open bars: control group, hatched bars: single hPTH(1–34) injection group, black bars: daily
hPTH(1–34) injected group. n = 7–8 for each group.
Fig. 2. Effects of PTHadministration on the distribution of osterix-positive osteoblasts on the endosteal bone surface of the diaphysis of the femur. (A) Immunoﬂuorescence of osterix in the
cortical bone area in the control (control) and daily hPTH(1–34) injection group (PTH) on day 5. Green cells are osterix-positive cells. The black area in the right half represents cortical
bone, and the red area in the left half shows bonemarrow.Negative control shows the section incubatedwith nonimmunized rabbit IgG as a substitute for theprimary antibody. Scale bars:
50 μm. Time course of the changes in the number of osterix-positive osteoblasts on the endosteal surface per mm in the anterior region (B) and posterior region (C) of the cortical bone.
Open bars: control group, hatched bars: single hPTH(1–34) injection group, black bars: daily hPTH(1–34) injection group. n = 7–8 for each group.
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water and food (CRF-1, standard diet for rats, Oriental Yeast,
Tokyo, Japan). The animals were allowed to acclimate to their envi-
ronment for 1 week before the start of the experiments. The exper-
imental protocols were approved by the Experimental Animal
Ethics Committee at Asahi Kasei Pharma Corp. and conducted in ac-
cordance with the guidelines concerning the management and han-
dling of experimental animals.
2.2. Experimental design
Rats in Groups 1 and 2 were euthanized on day 1 after adminis-
tration of saline (Group 1) or hPTH(1–34) 30 μg/kg (Group 2) on
day 0. Rats in Groups 3–5 were euthanized on day 3 after daily ad-
ministration of saline on days 0, 1, and 2 (Group 3), daily adminis-
tration of hPTH(1–34) 30 μg/kg on days 0, 1, and 2 (Group 4), or
single administration of hPTH(1–34) 30 μg/kg on day 0 followed
by daily administration of saline on days 1 and 2 (Group 5). Rats
in Groups 6–8 were euthanized on day 5 after daily administration
of saline on days 0 to 4 (Group 6), daily administration of hPTH
(1–34) 30 μg/kg on days 0 to 4 (Group 7), or single administration
of hPTH(1–34) 30 μg/kg on day 0 followed by daily administration
of saline on days 1 to 4 (Group 8). The hPTH(1–34) was adminis-
tered by subcutaneous injection. The euthanasia was performed
24 h after the last administration. After euthanasia, the both femurs
were dissected. One sample was ﬁxed in 4% paraformaldehyde,
decalciﬁed in 20% ethylenediaminetetraacetic acid (EDTA) at 4 °C
for 5 weeks, and then embedded in parafﬁn. Longitudinal 4 μm se-
rial sections were sliced and subjected to hematoxylin and eosin
(H&E) and immunoﬂuorescent stains. Another sample was ﬁxed in
70% ethanol, stained in Villanueva bone stain, dehydrated in a
graded ethanol series, defatted in acetone, and embedded in methyl
methacrylate (Wako Pure Chemical Industries, Osaka Japan). Thin
sections (5 μm) were cut from sagittal sections of the femur andFig. 4. Effects of hPTH(1–34) administration on the distribution of sclerostin-positive osteoc
sclerostin-positive osteocytes in the control and hPTH(1–34) administration groups (1 day aft
in the left half denotes bone marrow. Sclerostin-positive cells are shown in green. The nucleu
right hand yellow line delineates a distance 200 μm away. Negative control shows the section
bars: 50 μm. Time course of the changes in the number of sclerostin-positive osteocytes at t
cortical bone. Open bars: control group, hatched bars: single hPTH(1–34) injection group,
performed by Student's t-test [control group versus daily hPTH(1–34) injection group on day
compared by Dunnett's multiple comparisons test. *p b 0.05, **p b 0.01. n.s.: not signiﬁcant. n =these samples were then prepared for conventional bone
histomorphometric analyses.
2.3. Immunoﬂuorescence studies
For immunohistochemistry, the following antibodies were used as
primary antibodies: a rabbit polyclonal antibody against Sp7/osterix
(ab22552, Abcam, Cambridge, MA), and a goat polyclonal antibody
against SOST/sclerostin (AF1589, R&D systems, Minneapolis, MN).
Goat anti-Rabbit IgG AlexaFluor 488 and Rabbit anti-Goat IgG
AlexaFluor 488 (Invitrogen, Carlsbad, CA) were used as secondary anti-
bodies (1:1000). Sections were counterstained with propidium iodide
(PI) (Invitrogen) to stain the nuclei. Tiling imaging of immunostained
bone sections was performed using the Axioskop2 instrument (Carl
Zeiss, Oberkochen, Germany). Histomorphometric measurements
were performed in the 3mm2 region (2mm×1.5mm) in the secondary
spongiosa region, which was 2 mm away from the growth plate of the
proximal femur, and in the diaphysis of the cortical bone region,
which was 10 mm away from the growth plate of the proximal femur.
For negative controls, nonimmunized rabbit IgG or goat IgG was used
as a substitute for the primary antibody.
2.4. Measurement of bone metabolic markers and biochemical assay of se-
rum samples
The bone metabolic markers and biochemical data were measured
in serum samples obtained fromGroups 6, 7, and 8. Theblood samplings
were performed before the daily administration of saline or hPTH(1–
34) on days 0 to 3. Itwas also performed at 6 h after theﬁrst administra-
tion of saline or hPTH(1–34) on day 0. The sampling on day 5 was per-
formed at 24 h after the day 4 administration. All rats were fasted for at
least 6 h before blood collection. Serumwas obtained by centrifugation
of the collected blood samples from the subclavian vein according to theytes at the endosteal surface of cortical bone in the femur diaphysis. (A) Distribution of
er the injection). The black area in the right half represents cortical bone and the red area
s is red. In each panel, the left hand yellow line demarcates the endosteal surface and the
incubated with nonimmunized goat IgG as a substitute for the primary antibody. Scale
he endosteal surface per mm in the anterior region (B) and posterior region (C) of the
black bars: daily hPTH(1–34) injection group. Statistical analyses for two groups were
1]. †p b 0.05, ††p b 0.01. Statistical analyses for data sets with more than two groups were
7–8 for each group.
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and stored at−80 °C until analysis.
The serum level of osteocalcin (OC) was determined using an
osteocalcin rat ELISA system (GE Healthcare, Piscataway, NJ, USA). The
serum level of sclerostin (SOST) was measured using Mouse/Rat SOST
Quantikine ELISA Kit (R&D Systems, Minneapolis, MN). The following
serum biochemical assays were performed: inorganic phosphorus (Pi)
using L-type Wako Pi (Wako Pure Chemical Industries, Osaka, Japan),
calcium (Ca) using Calcium E-HA test Wako (Wako Pure Chemical In-
dustries), alkaline phosphatase (ALP) activity using L-type Wako ALP ∙ J
(Wako Pure Chemical Industries). All assays were performed according
to the manufacturer's instructions.
2.5. Bone histomorphometric analyses
Histomorphometric measurements were performed in the cancel-
lous bone tissue in the secondary spongiosa region (2 ± 1 mm from
the growth plate) and the cortical bone tissue at the diaphysial region
(10 ± 0.5 mm from the growth plate) of the femur. The following pa-
rameters were measured in the cancellous bone:bone volume [BV/TV
(%)], osteoid thickness [O.Th (μm)], osteoid surface [OS/BS (%)], and os-
teoblast surface [Ob.S (μm) andOb.S/BS(%)]. In the cortical bone, osteoid
thickness [O.Th (μm)] and osteoid surface [OS/BS (%)] were measured
(Parﬁtt et al., 1987). These parameters were assessed in the
undecalciﬁed sections. We also measured osteoblast number [N.Ob/BS
(N/mm)] in the decalciﬁed parafﬁn sections used for immunohisto-
chemical studies.Fig. 5. Bone histomorphometric analyses of cancellous bone (A) and cortical bone (B). Bone hi
bone volume, Ob.S: osteoblast surface, Ob.S/BS: osteoblast number: N.Ob/BS, osteoblast surfac
bars: single hPTH(1–34) injection group, black bars: daily hPTH(1–34) injection group. St
**p b 0.01. n = 7–8 for each group.2.6. Statistical analysis
The data are presented asmean± standard errors ofmean. Data sets
with two groups were compared by Student's t-test. Data sets with
more than two groups were compared by one-way analysis of variance
followed by Dunnett'smultiple comparisons test. p values less than 0.05
were considered signiﬁcant.
3. Results
3.1. The effects of hPTH(1–34) on the localization of osterix-expressing cells
in cancellous bone
In the control group, osterix-positive cells were sparsely distributed
in the bone marrow (Fig. 1A, B). Administration of hPTH(1–34) signiﬁ-
cantly increased the number of osterix-positive cells in the bone mar-
row on day 1 after the injection (Group 2) (Fig. 1A, B). The osterix-
positive cells tended to distribute in the vicinity of bone surface, and
some cells formed clusters. On day 3 after daily administration of
hPTH(1–34) (Group 4), the number of osterix-positive cells in the
bone marrow signiﬁcantly decreased compared to that on day 1
(Group 2), but it was still signiﬁcantly greater than that of the control
group on day 3 (Group 3) (Fig. 1A, B). On day 5 after daily injections
of hPTH(1–34) (Group 7), the number of osterix-positive cells in bone
marrow signiﬁcantly decreased compared to that of day 1 (Group 2),
and its level went down to that in control group (Group 6) (Fig. 1A,
B). A single injection of hPTH(1–34) on day 0 increased the number ofstomorphometric analysis was conducted as described in Materials and Methods. BV/TV:
e, O.Th: osteoid thickness, and OS/BS: osteoid surface. Open bars: control group, hatched
atistical analyses were performed by Dunnett's multiple comparisons test. *p b 0.05,
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to that in control group (Group 3), though its stimulatory effectwas sig-
niﬁcantly smaller compared to the daily injection on day 3 (Group 4) by
Student's t-test (p b 0.05) (Fig. 1B). The stimulatory effect of a single in-
jection of hPTH(1–34) diminished on day 5 (Group 8)(Fig. 1B).
The number of osterix-positive cells on the cancellous bone surface
showed no signiﬁcant difference among groups of control and hPTH
(1–34) administration groups by single or daily injection during the ex-
perimental period (Fig. 1A, C).
Negative controls whichwere incubated with nonimmunized rabbit
IgG as a substitute for the primary antibody exhibited no immunoreac-
tion as shown in Fig. 1A.
3.2. The effects of hPTH(1–34) on the localization of osterix-expressing cells
in cortical bone
Osterix-positive cells were more frequently distributed on the end-
osteal bone surface than the periosteal region in the cortical bone.
Since the number of osterix-positive cells on the endosteal bone surface
was greater at the posterior (30–40%) than that at the anterior (10–
20%) region of the femur in the control group (Fig. 2B, C), we counted
osterix-positive osteoblasts on the endosteal surface separately at ante-
rior and posterior regions. We found no signiﬁcant difference in the
number of osterix-positive cells on these endosteal surfaces (Fig. 2A,
B, C).
3.3. The effects of hPTH(1–34) on the localization of sclerostin-expressing
cells in cancellous bone
In the control group, the expression of sclerostin was observed
exclusively in osteocytes in the cancellous bone area, but the inci-
dence of positive osteocytes was very small (10–15% of total osteo-
cytes) (Fig. 3A, B). Treatment with hPTH(1–34) induced no
signiﬁcant change in the number of sclerostin-positive osteocytes
in cancellous bones among the groups tested (Fig. 3A, B). NegativeFig. 6. Effects of hPTH(1–34) administration on serum markers. Time courses of the changes
phosphorus (E). Closed circles: control group, closed squares: single hPTH(1–34) injection gr
control group were performed by Dunnett's multiple comparisons test on day 5. *p b 0.05, **pcontrols which were incubated with nonimmunized goat IgG as a
substitute for the primary antibody exhibited no immunoreaction
as shown in Fig. 3A.3.4. The effects of hPTH(1–34) on the localization of sclerostin-expressing
cells in cortical bone
There were many sclerostin-positive osteocytes in both anterior
and posterior regions of the in femoral cortical bone (~70% of total
osteocytes) (Fig. 4A, B, C, and Supplemental Fig. 1A, B, C). We
counted the number of sclerostin-positive osteocytes at the full
thickness areas of the sagittal cortical bone sections from endosteal
surface to periosteal surface (Supplemental Fig. 1A, B, C). Adminis-
tration of hPTH(1–34) signiﬁcantly decreased the number of
sclerostin-positive osteocytes at both the anterior and posterior re-
gions of the cortical bone on days 1 (Group 2) and 3 (Group
4) after daily hPTH(1–34) injection, but no signiﬁcant changes on
day 5 after daily injections (Group 7) (Supplemental Fig. 1A, B, C).
A single injection of hPTH(1–34) signiﬁcantly decreased the number
of sclerostin-positive osteocytes in only the posterior region of the
cortical bone on days 3 (Group 5) (Supplemental Fig. 1B, C).
Since the effect of hPTH(1–34) on the reduction of sclerostin-
positive osteocytes was more prominent at the endosteal and the peri-
osteal regions than the central region in the cortical bone, we next in-
vestigated the distribution of the sclerostin-positive osteocytes at the
endosteal region (200 μm area from the endosteal surface). In this
study, daily hPTH(1–34) treatments signiﬁcantly decreased the number
of sclerostin-positive osteocytes on days 1, 3, and 5 after the injections
in posterior region (Fig. 4A, C), and on days 1 and 5 at anterior region
(Fig. 4B). A single hPTH(1–34) treatment also induced a reduction on
days 3 and 5 after the injection in both anterior and posterior regions
(Fig. 4B, C). Negative controls which were incubated with
nonimmunized goat IgG as a substitute for the primary antibody exhib-
ited no immunoreaction as shown in Fig. 4A.in alkaline phosphatase (A), osteocalcin (B), sclerostin (C), calcium (D), and inorganic
oup, closed triangles: daily hPTH(1–34) injection group. Statistical analyses compared to
b 0.01. n = 7–8 for each group.
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Fig. 5 summarizes the bone histomorphometric analyses of the can-
cellous bone area (A) and cortical bone area (B) on day 5 after hPTH(1–
34) administration. In cancellous bone, hPTH(1–34) administration in-
duced no signiﬁcant change in bone volume (BV/TV) among the groups,
but daily hPTH(1–34) administrations increased osteoblast surface (Ob.
S), osteoblast surface (Ob.S/BS), osteoblast number (N.Ob/BS), osteoid
thickness (O.Th), and osteoid surface (OS/BS) compared to those in
the control group (Fig. 5A). A single injection of hPTH(1–34) signiﬁ-
cantly increased osteoid surface(OS/BS), but induced no signiﬁcant
change in osteoblast surface (Ob.S), osteoblast surface (Ob.S/BS), osteo-
blast number(N.Ob/BS), or osteoid thickness(O.Th) compared to that of
the control group in cancellous bone area (Fig. 5A). In cortical bone,
hPTH(1–34) administration increased osteoid thickness (O.Th), but no
signiﬁcant changes in osteoid surface (OS/BS) at the endosteal surface
(Fig. 5B).
3.6. The effects of hPTH(1–34) on serum markers
Serum levels of osteocalcin, which is a bone formation marker,
showed no signiﬁcant difference among the control group, single
hPTH(1–34) injection group, and daily hPTH(1–34) injection group
until day 3 after the administration. The daily hPTH(1–34) injection
group had a signiﬁcantly increased serum osteocalcin level on day 5
compared to that of the control and single hPTH(1–34) injection
group (Fig. 6B). Serum sclerostin levels also showed no signiﬁcant
changes among the control group, single hPTH(1–34) injection group,
and daily hPTH(1–34) injection group until day 3 after the administra-
tion, while the daily hPTH(1–34) injection group had a signiﬁcantly de-
creased serum sclerostin level on day 5 compared to that of the control
and single hPTH(1–34) injection groups (Fig. 6C). There were no signif-
icant differences in serum levels of alkaline phosphatase activity
(Fig. 6A), calcium (Fig. 6D), or inorganic phosphorus (Fig. 6E) among
the control group, single hPTH(1–34) injection group and daily hPTH
(1–34) injection group during the experiments.
4. Discussions
One of the major actions of PTH-induced anabolic bone action is
stimulation of osteoprogenitor cells in bone marrow (Silva and
Bilezikian, 2015; Nishida et al., 1994; He et al., 2013), but characteriza-
tion of such progenitors has not been well documented. In the present
study, we showed that hPTH(1–34) administration increased the num-
ber of osterix-positive cells in the bone marrow as early as day 1 after
hPTH(1–34) injection (Fig. 1A, B). Mizoguchi et al. (2014) recently re-
ported that osterix-expressing cells in the bone marrow of adult mice
are osteolineage-restricted cells that lack the differentiation potential
to become other mesenchymal cells. These ﬁndings suggest that the
osterix-positive cells in bone marrow increased by hPTH(1–34) injec-
tion are osteoprogenitors, and such increment is an integral part of
PTH-induced anabolic bone action.
Sclerostin is one of the target molecules related to PTH anabolic
action (Silva and Bilezikian, 2015; Jilka, 2007; Kousteni and
Bilezikian, 2008; Kramer et al., 2010; Ke et al., 2012; Weivoda and
Oursler, 2014; Tu et al., 2015; Bellido et al., 2005; Keller and
Kneissel, 2005; Silvestrini et al., 2007; Drake et al., 2010; Leupin
et al., 2007; Ardawi et al., 2012), but there has been limited informa-
tion about the effects of PTH administration on the precise distribu-
tion of sclerostin-positive cells in bone. Bellido et al. (Bellido et al.,
2005) reported that continuous infusion of hPTH(1–34) to mice for
4 days decreased the expression of Sost mRNA and sclerostin by
Western blotting in vertebrate bone, but 4 daily administrations in-
duced no apparent reduction of Sost mRNA and sclerostin protein.
They also showed that continuous injection induced dramatic de-
crease in sclerostin-positive osteocytes in cancellous bones byimmunohistochemistry, but intermittent treatment showed mini-
mal effect on decrease in sclerostin-positive osteocytes in cancellous
bone without any speciﬁc description about its distribution in corti-
cal bones (Bellido et al., 2005). Keller et al. reported that long-term
intermittent hPTH(1–34) injections into estrogen-deprived rats in-
duced a sustained downregulation of Sost mRNA in femoral cortical
bone (Keller and Kneissel, 2005). Since these reports implied that
the effects of intermittent administration of PTH on distribution of
sclerostin-positive osteocytes differ depending on parts of bone,
we compared the distribution of sclerostin-positive osteocytes be-
tween cancellous bone and cortical bone after intermittent adminis-
tration of hPTH(1–34). This study revealed that intermittent
administration of hPTH(1–34) induced signiﬁcant reduction in the
number of sclerostin-positive osteocytes in cortical bone but not in
cancellous bone (Figs. 3 and 4). We also showed the reduction in
serum level of sclerostin on day 5 after daily administration of
hPTH(1–34) (Fig. 6C). Apparent decrease in the number of
sclerostin-positive osteocytes in cortical bone might reﬂect the re-
duction of the serum sclerostin level at early phase of PTH-induced
anabolic action. Collectively, the intermittent administration of
hPTH(1–34) more preferentially reduced the number of sclerostin-
positive osteocytes in cortical bone than cancellous bone, and thus
the increase in the osterix-positive osteoprogenitors in bone mar-
rowmight play more important role in anabolic bone action induced
by hPTH(1–34) at early phase of the administration.
Although bone histomorphometric analyses in this study revealed
that hPTH(1–34) injections induced no signiﬁcant change in the volume
of cancellous bone on day 5 after hPTH(1–34) administration, daily in-
jections of hPTH(1–34) signiﬁcantly increased the parameters related
to bone formation, including osteoblast surface, osteoid thickness, and
osteoid surface in cancellous bone, and only osteoid thickness in cortical
bone. Signiﬁcant increase in serum osteocalcin level on day 5 after daily
injections of hPTH(1–34) may be due to the stimulation of bone forma-
tion in cancellous bones. These ﬁndings imply that the anabolic action of
hPTH(1–34) ﬁrst appears in cancellous bone via elevated levels of
osterix-positive osteoprogenitors and subsequent differentiation into
mature osteoblasts, while hPTH(1–34) anabolic action on cortical
bone may be delayed because several signaling pathways, including
the Wnt pathway, are activated after sclerostin downregulation. Only
a limited number of reports investigated the effects of hPTH(1–34) on
cancellous and cortical bones within 5 days after the hPTH(1–34) injec-
tion. Toromanoff et al. (Toromanoff et al., 1998) demonstrated that daily
hPTH(1–34) injections increased the bonemineral density (BMD) of fe-
murs on days 10 and 15 after hPTH(1–34) administration, but therewas
no change on day 5. These results are consistent with our results. Inter-
estingly, Kim et al. found that intermittent hPTH(1–34) administration
converts quiescent lining cells into mature osteoblasts at the periosteal
region of femurs by tracing osteoblast-lineage cells using ROSA26R re-
porter mice crossed with Dmp1-CreERt2 mice (SW et al., 2012). This
ﬁnding may reﬂect an early phenomenon of the anabolic action of
hPTH(1–34) at the periosteal region of cortical bone.5. Conclusions
This study suggested that the increase in osterix-positive
osteoprogenitors in cancellous bone and the decrease in sclerostin-
positive cells in cortical bone play important roles in hPTH(1–34)-in-
duced anabolic action on osteogenesis at early phase.
Supplementary data to this article can be found online at http://dx.
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